Comparative Expression of Apoptotic Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma
Lung cancer is still an oncology challenge. A 5-year survival reaches less than 20 % of patients. Apoptosis disturbances are a key step in cancer development. The evaluation of apoptosis markers has a great potential in lung cancer. The goal of our study was a comparative evaluation of apoptosis regulators: p53, Bcl-2, Bax, COX-2, and survivin in lung adenocarcinoma (AC) and squamous cell carcinoma (SCC). We also evaluated the relationship between apoptosis markers and clinicopathological parameters. Fifty six patients with non-small cell lung cancer (NSCLC) were included into the study (20 women and 36 men). AC was diagnosed in 30 and SCC in 26 cases. The evaluation of markers was performed using an immunohistochemical method on paraffin embedded tissue specimens. We used monoclonal antibodies for p53, bcl-2, and COX2-proteins (clone DO7, bcl-2/100/D5, and 4H12, respectively), Bax (B-9 clone) and survivin (clone 12C4). The results of immunostaining were viewed by light microscopy. We revealed significantly more frequent expression of Bax and survivin in lung AC than SCC (p < 0.01 and p < 0.019). Bcl-2 immunoreactivity was seen more often in AC without lymph node metastases than with metastases (p = 0.046). There was no correlation between the apoptosis markers and gender or the presence of vessel emboli. A greater variability in markers expression was seen in lung AC than SCC. There were significant differences in the Bax and survivin expression in the two major pathological types of NSCLC. We did not revealed any correlation between the markers and TNM characteristics, accept for Bcl-2 presence along with the lymph node involvement in the AC group.
KeywordsBax Bcl-2 COX-2 Immunohistochemistry Lung cancer p53 Survivin
- Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ (2008) Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy. Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848–855CrossRefPubMedGoogle Scholar
- GLOBCAN (2012) Estimated cancer incidence, mortality and prevalence worldwide, WHO, IARC. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed on 10 May 2014
- Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM (2011) Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol 10:4320–4326CrossRefGoogle Scholar
- Milas I, Komaki R, Hachiya T, Bubb SR, Ro JY, Langford L, Sawaya R, Putnam JB, Allen P, Cox JD, McDonnell TJ, Brock W, Hong WK, Roth JA, Milas L (2003) Epidermal growth factor receptor, cyclooxygenase-2, and Bax expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res 9:1070–1076PubMedGoogle Scholar
- Molina MA, Simonetti S, Quiroga V, Viteri S, Campelo RG, Sanchezm J, Benlloch S, Aldeguer E, Taron M, Rosell R (2010) Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations. J Clin Oncol 28(suppl):abstr e18063Google Scholar